Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges

Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges
RestartResume

Targeted therapies for oncogenic mutations are emerging as a promising way to manage non-small cell lung cancer, but they still come with challenges.

  • Overview

    Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges.

    To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free